Unicycive Therapeutics Inc
About Unicycive Therapeutics Inc
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
- Ticker
- UNCY
- Trading on
- NASDAQ
- ISIN
- -
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Dr. Shalabh K. Gupta M.D., MPA
- Headquarters
- 1975 West El Camino Real, Mountain View, CA, United States, 94040
- Employees
- 21
- Website
- https://unicycive.com
Metrics
Analyst Insights & forecasts
Based on information from 10 analysts.
Earnings per share (EPS) forecast
| Q3 • 25 | Q4 • 25 | Q1 • 26 | Q2 • 26 | |
|---|---|---|---|---|
| Actual | -$0.33 | -$0.82 | -$0.54 | -$0.06 |
| Expected | -$0.53 | -$0.46 | -$0.48 | -$0.34 |
| Surprise | 37.74% | -78.26% | -11.47% | 82.35% |
| Beat | Missed | Missed | Current |
Financial Performance
| Q1 • 26 | Q2 • 26 | QoQ growth | |
|---|---|---|---|
| Revenue | $0M | $0M | NaN% |
| Net income | $-12.8M | $-1.7M | -86.57% |
| Profit margin | -∞% | -∞% | NaN% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.
FAQs
01How much is a Unicycive Therapeutics Inc share?
Unicycive Therapeutics Inc shares are currently traded for undefined per share.
02How many shares does Unicycive Therapeutics Inc have?
Unicycive Therapeutics Inc currently has 27.4M shares.
03Does Unicycive Therapeutics Inc pay dividends?
No, Unicycive Therapeutics Inc doesn't pay dividends.
04What is Unicycive Therapeutics Inc 52 week high?
Unicycive Therapeutics Inc 52 week high is $8.74.
05What is Unicycive Therapeutics Inc 52 week low?
Unicycive Therapeutics Inc 52 week low is $3.33.
06What is the 200-day moving average of Unicycive Therapeutics Inc?
Unicycive Therapeutics Inc 200-day moving average is $6.03.
07Who is Unicycive Therapeutics Inc CEO?
The CEO of Unicycive Therapeutics Inc is Dr. Shalabh K. Gupta M.D., MPA.
08How many employees Unicycive Therapeutics Inc has?
Unicycive Therapeutics Inc has 21 employees.
09What is the market cap of Unicycive Therapeutics Inc?
The market cap of Unicycive Therapeutics Inc is $97.2M.
10What is the P/E of Unicycive Therapeutics Inc?
The current P/E of Unicycive Therapeutics Inc is null.
11What is the EPS of Unicycive Therapeutics Inc?
The EPS of Unicycive Therapeutics Inc is -$1.72.
12What is the PEG Ratio of Unicycive Therapeutics Inc?
The PEG Ratio of Unicycive Therapeutics Inc is null.
13What do analysts say about Unicycive Therapeutics Inc?
According to the analysts Unicycive Therapeutics Inc is considered a buy.
